Spelling suggestions: "subject:"colon (anatomy) aancer enetic aspects."" "subject:"colon (anatomy) aancer benetic aspects.""
11 |
Molecular mechanisms of autophagy mediated by silencing of EEF2K in colon cancer cells / CUHK electronic theses & dissertations collectionJanuary 2014 (has links)
Eukaryotic translation elongation factor-2 (EEF2) is regulated through phosphorylation by a specific kinase known as eukaryotic elongation factor-2 kinase (EEF2K), leading to translational down regulation. Currently, it has been reported that EEF2K could promote the autophagic survival in breast and glioblastoma cell lines. However, the precise function of EEF2K in cancer as well as the related mechanism is still poorly understood. Colorectal cancer is the third common malignant disease worldwide and more than half of the patients with colorectal cancer require chemotherapy after surgery. However, de novo or acquired resistance to the agents is common. Discovery of novel targets for the chemotherapeutic intervention or treatment of colorectal cancer is highly warranted. In this study, the role of EEF2K as well as the underlying mechanism involved was evaluated in HT-29 and HCT-116 human colon cancer cells. Contrary to the reported autophagy-promoting activity of EEF2K in certain cancer cells, EEF2K is shown to negatively regulate autophagy in colon cancer cells as indicated by the increase of LC3-II levels, the accumulation of LC3 dots per cell, and the promotion of autophagic flux in EEF2K silenced cells. Moreover, the silencing of EEF2K promotes the cell viability, clonogenicity, cell proliferation and cell size in colon cancer cells. The silencing of BECN1 and ATG7 significantly reduce silencing of EEF2K induced LC3-II accumulation and cell survival. However, autophagy induced by EEF2K silencing does not potentiate the anticancer efficacy of the AKT inhibitor MK-2206. In addition, EEF2K overexpression decreases the cell survival and potentiates the antitumor efficacy of oxaliplatin. Autophagy induced by silencing of EEF2K is attributed to induction of protein synthesis, which results in ATP consumption and then actives AMPK-ULK1 pathway. This process appears independent of the suppression of MTOR activity and ROS generation. Silencing of AMPK or ULK1 significantly decreases EEF2K silencing-induced autophagy as well as cell survival in colon cancer cells. In conclusion, EEF2K negatively regulates autophagic survival through the AMPK-ULK1 pathway in colon cancer cells. This study provide useful information in understanding the role of EEF2K in colon cancer cells and suggests that upregulation of EEF2K activity may be developed a novel approach for the treatment of human colon cancer. / 真核延伸因子2激酶 (EEF2K) 通過磷酸化修飾真核延伸因子2 (EEF2) 來調控其活性,進而下調蛋白質翻譯延伸的速度。目前,有研究表明在乳腺癌和多形性膠質母細胞瘤中,EEF2K能夠誘導細胞自噬,並且這種類型的細胞自噬有助於細胞生存。然而,對於EEF2K在腫瘤中的精確作用以及它所涉及的分子機理仍然知之甚少,有待於進一步的研究。結直腸癌是全球第三大惡性腫瘤疾病,約有半數以上的患者需要手術後進行化學藥物治療。然而,患者對目前已有藥物的耐藥性十分普遍,因此,研發新的化學藥物靶點或者新的治療方法十分必要。在本課題研究中,EEF2K的功能及其所涉及的分子機理在人結腸癌細胞系HT-29和HCT-116上進行了闡釋。與在某些特定種類腫瘤細胞中EEF2K能夠誘導細胞自噬產生的現象相反,在EEF2K表達下調的人結腸癌細胞中,細胞自噬標記物LC3-II表達上升, 細胞中LC3斑點的聚集增多,並且細胞自噬流增強的現象,都表明EEF2K在這類腫瘤細胞中負調控細胞自噬。在結腸癌細胞中,EEF2K表達下調能夠增強細胞的活力,單細胞克隆的形成,細胞增殖以及細胞大小。此外,沈默BECN1和ATG7基因的表達都能夠減少EEF2K下調引發的LC3-II積累以及細胞增殖。然而,降低EEF2K表達所引發的細胞自噬並不能夠增強AKT抑制劑MK-2206抗腫瘤的效果。EEF2K的過表達能夠減少細胞增殖並且加強oxaliplatin的抗腫瘤藥效。沈默EEF2K引發的細胞自噬是通過誘導蛋白質的合成,導致ATP的消耗進而激活AMPK-ULK1細胞通路,與MTOR活性的抑制及ROS的產生無關。在結腸癌細胞中,降低AMPK或者ULK1的表達能夠消除EEF2K沈默所引起的LC3-II表達升高,細胞中LC3斑點聚集增多以及細胞增殖加強等現象。綜上所述,在人結腸癌細胞中,沈默EEF2K基因表達能夠通過激活AMPK-ULK1細胞通路,誘導有助於細胞存活的自噬現象產生。本課題研究對理解EEF2K在結腸癌細胞中的功能提供了有用的信息並且表明增強EEF2K的活性可以作為一種潛在的新的治療人結腸癌的方法。 / Liu, Xiaoyu. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2014. / Includes bibliographical references (leaves 116-131). / Abstracts also in Chinese. / Title from PDF title page (viewed on 16, November, 2016). / Detailed summary in vernacular field only.
|
12 |
Novel recurrent point mutation and gene fusion identified by new generation sequencing in colorectal cancer. / CUHK electronic theses & dissertations collectionJanuary 2013 (has links)
He, Jun. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2013. / Includes bibliographical references (leaves 136-156). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstract also in Chinese.
|
13 |
A novel amplification gene SLC12A5 promotes cell proliferation and tumor metastasis in colorectal cancer / CUHK electronic theses & dissertations collectionJanuary 2014 (has links)
Background & Aims: By whole genome sequencing, we identified for the first time that solute carrier family 12 member 5 (SLC12A5) gene located on chromosome 20q13.12 was amplified in colorectal cancer (CRC). We aimed to determine the amplification status of SLC12A5 and its clinical implication in CRC, and characterize the functional mechanisms of SLC12A5 in colorectal carcinogenesis. / Materials and Methods: Protein expression level of SLC12A5 was evaluated by immunohistochemistry. SLC12A5 amplification was verified by fluorescence in situ hybridization (FISH). The correlations between SLC12A5 expression and clinicopathologic parameters as well as the prognosis impact of SLC12A5 were analyzed in 195 CRC patients. The biological function of SLC12A5 in CRC cell lines were determined by cell viability, colony formation, invasion, migration, flow cytometry and in vivo tumorigenicity assays. Standard tail vein metastatic assay was performed to examine the effect of SLC12A5 in lung metastasis in nude mice. Western blot, luciferase reporter assays and human tumor metastasis PCR array were performed to evaluate SLC12A5 downstream effectors and related pathways. / Results: RT-PCR showed SLC12A5 was readily expressed in 7 of 9 CRC cell lines, but was absent in normal colorectal tissues. The mean protein expression level of SLC12A5 was significantly higher in primary CRCs as compared to their adjacent normal tissues. Amplification of SLC12A5 was detected in 40.8% (78/191) of primary CRCs by FISH, which was positively correlated with its protein overexpression (P < 0.001). Overexpression of SLC12A5 was positively associated with a more advanced TNM stage (P < 0.05). Multivariate Cox regression analysis showed that SLC12A5 overexpression was an independent predictor of poorer survival of CRC patients (P = 0.018). We further tested the biological function of SLC12A5 in human colon cancer cells. Ectopic expression of SLC12A5 in colon cancer cells SW480 and SW1116 increased proliferation and colony formation. Silencing SLC12A5 expression in HCT116 by siRNA had the opposite effects in vitro, and knockdown of SLC12A5 by shRNA significantly inhibited xenograft tumor growth in nude mice. We further revealed that SLC12A5 inhibited apoptosis of colon cancer cells by mediating apoptosis-inducing factor (AIF) and endonuclease G (EndoG) -dependent apoptotic signaling pathway. Moreover, gain-and loss-of-function experiments showed that SLC12A5 enhanced cell invasion and migration in vitro. Knockdown of SLC12A5 by shRNA significantly inhibited lung metastasis in nude mice. SLC12A5 promoted tumor metastasis through regulating key elements of the matrix architecture, such as matrix metallopeptidase and fibronectin. / Conclusion: We have identified a novel amplification gene SLC12A5 which is overexpressed in CRC. SLC12A5 may be an independent prognostic marker for CRC and may play a pivotal oncogenic role in colorectal carcinogenesis by inhibiting apoptosis and promoting metastasis. / 背景和目的:通過對結直腸癌進行全基因組測序,我們首次發現位於染色體20q13.12的SLC12A5基因在結直腸中擴增。本研究旨在探索SLC12A5在結直腸癌中的擴增情況和臨床意義,并進一步研究SLC12A5在結直腸癌發生發展中的作用機制。 / 材料和方法:採用免疫组化方法檢測SLC12A5的蛋白表达水平。應用熒光原位雜交方法驗證SLC12A5基因的擴增情況。在195例結直腸癌患者中对SLC12A5表达與临床病理關係及其對預後的影響其进行分析。通过檢測細胞活力、細胞集落形成實驗、侵襲實驗、遷移實驗、流式細胞術和體內成瘤實驗以研究SLC12A5在結直腸癌中的生物学功能。進而通過免疫印跡、熒光素酶報告實驗和人腫瘤轉移的PCR陣列,探索SLC12A5調控的基因和相关途径。 / 结果:我們採用RT-PCR方法檢測SLC12A5在9株結直腸癌細胞株的表達情況,SLC12A5在7株結直腸癌細胞株中穩定表達,但是在正常大腸組織中表達沉默。SLC12A5在結直腸中的平均蛋白表達水平顯著高於其鄰近的正常組織。通過熒光原位雜交方法,在40.8% (78/ 191)的結直腸癌中檢測到SLC12A5的擴增,該基因的擴增與其蛋白高表達水平呈正相關關係。SLC12A5高表達水平跟晚期TNM分期密切相關(P <0.05)。多因素Cox回歸分析表明,SLC12A5高表達是結直腸癌患者較差的生存的獨立預測因子(P = 0.018)。我們進一步在人結腸癌細胞株中檢測SLC12A5的生物功能。在結腸癌細胞SW480和SW1116中過度表達SLC12A5促進細胞增殖和集落形成。siRNA敲低HCT116 細胞SLC12A5的表達在體外實驗中有相反的效果。此外,shRNA敲低SLC12A5的表達顯著抑制裸鼠移植瘤的生長。我們進一步發現,SLC12A5通過介導凋亡誘導因子(AIF)和核酸內切酶G(EndoG)-依賴的細胞凋亡信號轉導通路抑制結腸癌細胞的凋亡。此外,功能獲得性和功能缺失性的體外實驗表明,SLC12A5促進腫瘤細胞的侵襲和遷移。尾靜脈注射實驗表明shRNA敲低SLC12A5的表達顯著抑制裸鼠肺轉移。SLC12A5通過調節基質結構的關鍵因子,如基質金屬蛋白酶和纖維連接蛋白,促進腫瘤轉移。 / 结论:我們發現了一個新的擴增基因SLC12A5,該基因在結直腸癌中高表達。SLC12A5是結直腸癌的一個獨立的預後標誌物。SLC12A5通過抑制細胞凋亡和促進腫瘤轉移,在結直腸癌的發生發展中起了舉足輕重的致癌作用。 / Xu, Lixia. / Thesis Ph.D. Chinese University of Hong Kong 2014. / Includes bibliographical references (leaves 107-120). / Abstracts also in Chinese. / Title from PDF title page (viewed on 05, October, 2016). / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only. / Detailed summary in vernacular field only.
|
14 |
DNA mismatch repair-dependent responses to the food-borne carcinogen 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in the mouseSmith-Roe, Stephanie L. 02 May 2006 (has links)
Graduation date: 2006
|
15 |
Profiling of gene expression changes in human colon crypt maturation and study of their dysregulation in tumourigenesisLi, Sze-wing, Vivian., 李思穎. January 2008 (has links)
published_or_final_version / Pathology / Doctoral / Doctor of Philosophy
|
16 |
Expression of the DNA mismatch repair protein MLH1 in serrated polyps of the colon: an immunohistochemical studyChan, Ling-fung., 陳凌鋒. January 2005 (has links)
published_or_final_version / Medical Sciences / Master / Master of Medical Sciences
|
17 |
Genome-wide association study on colorectal cancer in the Hong Kong Chinese populationChoi, Siu-chung, 蔡兆聰 January 2012 (has links)
Colorectal cancer (CRC) is the second most common cancer in Hong Kong. While high-penetrance germline mutations account for up to 6% of cases, much of the variation in genetic risk may be attributable to multiple low-penetrance variants. Previous genome wide association studies (GWAS) have identified a number of CRC susceptibility alleles in Caucasian populations. Our GWAS investigated the association between genetic variants with CRC risk in the Han Chinese population in Hong Kong. In Stage I, genomic DNA samples from 455 female Chinese CRC subjects were genotyped using the Illumina 610 Quad SNP chip. Association analysis was performed on 439 cases and 771 general population female controls recruited for a study on bone mineral density. Population stratification was examined through principal components analysis using EIGENSTRAT version 2.0. From the association results, 46 SNPs (Group 1) were selected for follow-up replication (Stage II), together with 10 SNPs (Group 2) from previous GWAS studies. Genomic DNA samples from 3,571 Chinese subjects were genotyped using Sequenom MassARRAY system. Association analysis was performed on 1,505 cases and 1,452 controls. 5 SNPs (rs835378, rs2652007, rs2139273, rs2139273 and rs9286410) exceeded the genome-wide significance level in stage I, although none replicated in Stage 2, suggesting genotyping error. Results from stage II showed that the three most significant SNP were among those selected from the previous studies, yet their significance levels in Stage I were very weak . None of the SNPs selected from Stage I was significant at p<0.01 in Stage 2. Two composite scores of genetic susceptibility, one for each group of SNPs, were calculated in stage II genotype data, as the total number of high-risk alleles (according to the direction of effect in Stage I results or previous GWAS) present in an individual. Both composite scores were significantly associated with CRC risk in Stage 2 (Group 1, p=2.38 x 10-5, beta=0.046, SE=0.012; Group 2 p=1.06 x 10-7, beta=0.10, SE=0.019), suggesting that while we had insufficient power to confirm individual SNPs identified in our GWAS and the previous GWAS, these findings indicate that the SNP sets selected from Stage I results, as well as those selected from previous GWAS, contain SNPs with genuine effects on CRC risk. One SNP, rs10795668 (OR = 0.79 [CI] 95%:0.71 – 0.87 p=3.78 x 10-6), was significantly associated with CRC risk in Stage II after adjustment for multiple testing. Two further SNPs, rs6983267 and rs4939827, also achieved suggestive p-values in Stage II. All these SNPs were selected from previous GWAS in the Caucasian population, demonstrating that shared genetic factors operate for CRC in diverse populations. / published_or_final_version / Psychiatry / Master / Master of Philosophy
|
18 |
Identification of polycomb group protein CBX8 as a novel tumor suppressor in human colorectal cancerLi, Hung-sing, 李鴻陞 January 2014 (has links)
Polycomb group (PcG) proteins governs the regulation of diverse cellular functions, such as cell fate decision, cell cycle progression, maintenance of embryonic stem cell pluripotency, and DNA damage repair. Although aberrant expression of PcG proteins has been frequently reported in different cancer types, CBX8 is one of the least studied PcG family members in cancer. Recently, a study showed that forced expression of CBX8 in normal human and mouse fibroblasts demonstrated that cells could bypass senescence via INK4a-ARF repression; while another report demonstrated that CBX8 was involved in MLL-AF9-linked leukemogenesis. Despite accumulating evidence on CBX8-related carcinogenic functions, the role of CBX8 in solid cancers has not been investigated thus far. This study is therefore initiated to investigate and establish the functional role of CBX8 in colorectal cancer.
In this study, expression of CBX8 in 121 pairs of human CRC samples was analyzed by immunohistochemistry; and data were correlated with different clinicopathological parameters. To evaluate the functional effects of CBX8, CBX8 overexpressed and downregulated clones were established from three CRC cell lines. The in vitro effects of CBX8 on cell proliferation, cell cycle progression and apoptosis profiles were investigated; and the effects of CBX8 on tumorigenicity in vivo were further demonstrated in mice xenograft models.
The results showed that CBX8 expression was downregulated or loss in approximately 48.8% of human colorectal tumors, and downregulated or loss of CBX8 expression were mainly observed in tumors with intermediate to later stages (stage II to IV). Moreover, expression of CBX8 showed a significant inverse correlation with colorectal tumor sizes (P < 0.0001). Ectopic expression of CBX8 in CRC cell lines resulted in inhibition of cell proliferation, clonogenic ability and anchorage-independent growth, which are hallmarks of tumorigenesis. Conversely, downregulation of CBX8 promoted proliferation and clonogenic ability. Moreover, it was found that restoring CBX8 expression could induce G0/G1 arrest of cell cycle. The tumor suppressive role of CBX8 in colorectal cells was further demonstrated in vivo through subcutaneous and orthotropic mice tumor models; followed by immuno-staining of the proliferation marker Ki-67. To unveil the possible mechanisms behind the tumor suppressing effects of CBX8, two signalling pathways commonly engaged in CRC were evaluated. At least part of the effects could be attributed to the mediation of MAPK signaling pathway; whereas the Wnt signalling was not affected by CBX8.
This study demonstrated for the first time the loss of CBX8 expression in intermediate and late stage tumors, and was the first to report the tumor suppressing ability of CBX8 in solid cancers. The effects of CBX8 in this study were different to the functional implications reported in the current literature. This functional divergence in distinct cell types suggested a dynamic role of CBX8 depending on specific cellular context. / published_or_final_version / Surgery / Master / Master of Philosophy
|
19 |
Expression of vascular endothelial growth factor and its receptors in tumours張毅, Cheung, Ngai. January 1998 (has links)
published_or_final_version / Pathology / Master / Master of Philosophy
|
20 |
Characterization of long non-coding RNA H19 in epithelial to mesenchymal transition: 長非編碼RNA H19在上皮間充質轉化中的功能探究 / 長非編碼RNA H19在上皮間充質轉化中的功能探究 / CUHK electronic theses & dissertations collection / Characterization of long non-coding RNA H19 in epithelial to mesenchymal transition: Chang fei bian ma RNA H19 zai shang pi jian chong zhi zhuan hua zhong de gong neng tan jiu / Chang fei bian ma RNA H19 zai shang pi jian chong zhi zhuan hua zhong de gong neng tan jiuJanuary 2014 (has links)
Colorectal cancer (CRC), with an estimated 1.2 million new cases annually, is the third leading cause of cancer incidence and death worldwide. Generally, the majority of CRC patients are diagnosed at the advanced stages with poor prognosis and unfavorable response to multiple therapeutic drugs. In spite of increasing knowledge of the molecular mechanism for the tumorigenesis in CRC patients, the translation from basic science into clinical therapy has been limited for quite a long time. In order to develop novel treatment strategies against CRC, intensive and extensive attempts have been made in the past decades. / The epithelial to mesenchymal transition (EMT) is a multi-step process characterized by the loss of cell polarity, decreased cell-cell adhesion as well as enhanced migration and invasion capacity. It is well documented that EMT is essential for a variety of cellular biological events ranging from embryogenesis to tumor progression. The field of lncRNA is developing rapidly and currently it is one of the most intensively studied fields in the biomedical sciences. Emerging evidence indicates that the majority of human genome encodes thousands of non-protein-coding RNA transcripts, nevertheless, the function of long non-coding RNAs (lncRNAs) in orchestrating EMT progression remains elusive. Historically, the lncRNA H19 was the first identified imprinted non-coding RNA transcript in human, and the H19/IGF2 locus acted as an ideal paradigm for the investigation of genomic imprinting genes. In recent years, the expression profiling and functional characterization of the H19 gene in a variety of human diseases has been extensively studied. / In our studies, H19 was characterized as a novel regulator of EMT in colon cancer. We first observed significant mesenchymal characteristics in the methotrexate-resistant HT-29 cells. Interestingly, significant upregulation of H19 was observed in mesenchymal-like MTX resistant HT-29 cells. We subsequently demonstrated that after treatment of TGF-β1, one of the most widely used EMT inducers, H19 presented dramatic increase during the EMT progression. To further investigate the functional role of H19 in EMT, we generated the stable cell lines overexpressing H19 in colon cancer cells using retroviral infection. Stable overexpression of H19 significantly promoted EMT progression in two epithelial colon cancer cell lines HT-29 and HCT-116. However, overexpression of H19 did not affect cell proliferation as well as cell cycle progression. Further proteomics studies screened out that ectopic expression of H19 upregulated the protein level of Vimentin, a vital biomarker for mesenchymal cells. By using the bioinformatics study in combination with luciferase reporter assays, we demonstrated that H19 potentiated the expression of several core marker genes essential for mesenchymal cells by serving as a competing endogenous RNA(ceRNA), which builds up the missing link between the regulatory miRNA network and EMT progression. According to the results from xenograft tumor model and soft agar assay, stable expression of H19 reinforced the in vitro and in vivo tumor growth. Moreover, the investigation of clinical specimens verified that H19 RNA level was significantly increased in colon cancer tissues compared with corresponding adjacent normal tissues. Taken together, the above observations imply that the lncRNA H19, by acting as a competing endogenous RNA, is an important regulator which tightly modulated the expression of multiple important genes involved in EMT and it could probably serve as a novel therapeutic target against colon cancer. / 大腸癌每年有一百二十萬新增個案,是世界第三大癌症殺手。通常情況下,大部分大腸癌病人發現時已經處於晚期,該時期的癌症病人對多種臨床治療藥物已無法治愈。盡管關於大腸癌發病的分子生物學機制已經不斷完善,但如何從基礎研究轉化為臨床治療手段在很長一段時間內不可實現。為了進一步研究新的抗擊大腸癌治療手段,廣泛且深入的研究已經不斷開展。 / 上皮間充質轉化是一個多步驟的過程,該過程的典型特徵為失去細胞的極性,細胞間粘連減弱以及細胞爬行遷移能力的不斷加強。目前科學家已經知道上皮間充質轉化對於從胚胎發育到腫瘤發展都起著重要的作用。近年來,長非編碼RNA的研究不斷快速發展,已然成為醫學研究中最激烈的領域之一。眾多證據表明人體基因組編碼數以千計不編碼蛋白質的RNA轉錄體。然而,這些RNA轉錄體在上皮間充質轉化中的功能依然所知甚少。長非編碼RNA H19是人體內第一個被鑒別出來參與到基因印記的非編碼RNA。資料表明H19/IGF2位點是一個非常理想的研究基因印記的位點。近年來,H19在眾多癌症中的表達以及功能學研究已不斷湧現,同時也不斷取得令人鼓舞的研究成果。 / 在我們的研究中,H19被鑒定為大腸癌裏上皮間充質轉化過程中一個重要的參與者。通過研究甲氨蝶呤耐藥大腸癌HT-29細胞株,我們發現該HT-29耐藥細胞株有著顯著的間充質細胞特性。有趣的是,H19在該細胞株中有著顯著升高。我們隨後用經典的上皮間充質轉化誘導劑TGF-β1處理兩株大腸癌細胞,處理後H19亦有著顯著升高。為了進一步研究H19在上皮間充質轉化,通過使用逆轉錄病毒,我們建立H19的穩定表達細胞株。穩定表達H19顯著地促進了HT-29以及SW620大腸癌細胞株的上皮間充質轉化。然後,高水平表達(過表達)H19並不影響細胞的生長以及細胞周期的進程。進一步的蛋白質組學研究表明,過表達H19能促進間充質細胞一個重要標記基因Vimentin的表達。通過生物信息學以及熒光素酶報告基因實驗,我們證明了H19通過其競爭內源性RNA的作用,能夠促進間充質細胞所需的幾個重要基因的表達。該發現建立起了miRNA網絡以及上皮間充質轉化進程的交流網絡。通過異位移植以及軟瓊脂實驗,我們發現過表達H19能夠促進腫瘤細胞的生長。而在臨床大腸癌病人組織中,我們更發現H19在大腸癌病人組織中高表達。綜上所述,我們的結果證明H19這一長非編碼RNA,能夠通過其競爭內源性RNA的作用機制,從而調控上皮間充質轉化過程中的關鍵基因。同時H19亦有可能成為治療大腸癌的臨床新靶點。 / Liang, Weicheng. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2014. / Includes bibliographical references (leaves 95-124). / Abstracts also in Chinese. / Title from PDF title page (viewed on 24, October, 2016). / Liang, Weicheng.
|
Page generated in 0.0612 seconds